All In Biotech

Drug Trial Radar · NCT00049517

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia

A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification Prior to Risk-Allocated Autologous Stem Cell Transplantation

Last checked: Nov 20, 2026Latest source record: Jun 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 657 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

657

Actual

Start

Dec 19, 2002

Primary completion

Mar 2009

Study completion Dec 2019

Sponsor

Lead sponsor
Eastern Cooperative Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Giving combination chemotherapy before a stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the transplanted stem cells. When the healthy stem cells are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. If the patient's stem cells are to be transplanted, the patient is also treated with a monoclonal antibody, such as gemtuzumab ozogamicin, to kill any remaining cancer cells or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without gemtuzumab ozogamicin followed by stem cell transplant in treating acute myeloid leukemia. PURPOSE: This randomized phase III trial is studying combination chemotherapy, gemtuzumab ozogamicin, and stem cell transplant to see how well they work compared to combination chemotherapy and peripheral stem cell transplant alone in treating patients with acute myeloid leukemia.

Conditions

  • Leukemia

Interventions

  • sargramostimBiological

    Given IV or as an injection

  • busulfanDrug

    Given IV

  • cyclophosphamideDrug

    Given IV

  • cytarabineDrug

    Given as a continuous infusion

  • gemtuzumab ozogamicin (GO)Drug

    Given IV

  • DaunorubicinDrug

    Given intravenously daily for 3 days at a dose of either 45 or 90 mg/m2.

  • Autologous HCTProcedure

    Autologous hematopoietic cell transplantation

  • Allogeneic HCTProcedure

    Allogeneic hematopoietic cell transplantation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (Induction Phase)Time frame: Assessed during the first 4 months, then at least every three months for 2 years. then every six months until 5 years after study entry and every 12 months thereafter.
  2. Disease-free Survival (Consolidation Phase)Time frame: Assessed during the first 4 months, then at least every three months for 2 years. then every six months until five years after study entry, and every 12 months thereafter.

Locations

99 sites in 2 countries. Site status is shown where the registry gives one.

  • Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham

    Birmingham, Alabama

  • Mayo Clinic Scottsdale

    Scottsdale, Arizona

  • Aurora Presbyterian Hospital

    Aurora, Colorado

  • Penrose Cancer Center at Penrose Hospital

    Colorado Springs, Colorado

  • St. Anthony Central Hospital

    Denver, Colorado

  • Porter Adventist Hospital

    Denver, Colorado

  • Presbyterian - St. Luke's Medical Center

    Denver, Colorado

  • St. Joseph Hospital

    Denver, Colorado

  • Rose Medical Center

    Denver, Colorado

  • CCOP - Colorado Cancer Research Program

    Denver, Colorado

  • Swedish Medical Center

    Englewood, Colorado

  • St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center

    Grand Junction, Colorado

  • North Colorado Medical Center

    Greeley, Colorado

  • Sky Ridge Medical Center

    Lone Tree, Colorado

  • Hope Cancer Care Center at Longmont United Hospital

    Longmont, Colorado

  • McKee Medical Center

    Loveland, Colorado

  • St. Mary - Corwin Regional Medical Center

    Pueblo, Colorado

  • North Suburban Medical Center

    Thornton, Colorado

  • Exempla Lutheran Medical Center

    Wheat Ridge, Colorado

  • Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - West

    Boca Raton, Florida

  • Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - Main Campus

    Boca Raton, Florida

  • University of Florida Shands Cancer Center

    Gainesville, Florida

  • University of Miami Sylvester Comprehensive Cancer Center - Miami

    Miami, Florida

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University

    Chicago, Illinois

  • Hematology and Oncology Associates

    Chicago, Illinois

  • Evanston Northwestern Healthcare - Evanston Hospital

    Evanston, Illinois

  • Midwest Center for Hematology/Oncology

    Joliet, Illinois

  • Joliet Oncology-Hematology Associates, Limited - West

    Joliet, Illinois

  • North Shore Oncology and Hematology Associates, Limited - Libertyville

    Libertyville, Illinois

  • La Grange Oncology Associates - Geneva

    Naperville, Illinois

  • Cancer Care and Hematology Specialists of Chicagoland - Niles

    Niles, Illinois

  • Advocate Lutheran General Cancer Care Center

    Park Ridge, Illinois

  • Hematology Oncology Associates - Skokie

    Skokie, Illinois

  • Carle Cancer Center at Carle Foundation Hospital

    Urbana, Illinois

  • CCOP - Carle Cancer Center

    Urbana, Illinois

  • Fort Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana

  • Indiana University Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana

  • Tufts-NEMC Cancer Center

    Boston, Massachusetts

  • Borgess Medical Center

    Kalamazoo, Michigan

Showing 40 of 99 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.